FDA Determines Regulatory Review Period for PORTICO TRANSCATHETER AORTIC VALVE IMPLANT

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the PORTICO TRANSCATHETER AORTIC VALVE IMPLANT, a medical device, in accordance with federal regulations, following the submission of patent extension applications to the U.S. Patent and Trademark Office (USPTO).